Posts by tag
ribociclib
2 posts
Adding a CDK4/6 inhibitor to endocrine therapy improves outcomes in HR+ HER2– early-stage breast cancer
Adding the CDK4/6 inhibitor ribociclib to standard-of-care adjuvant endocrine therapy for treatment of hormone receptor-positive HER2-negative early-stage breast cancer reduced risk of recurrence by 25%. The phase III NATALEE study, abstract LBA500, presented at the ASCO 2023 Annual Meeting, held…
Round-up of prostate and breast cancer studies from ESMO 2021
The 2021 Congress of the European Society for Medical Oncology (ESMO), held 16‒21 September, featured studies that are likely to impact a broad spectrum of clinical practice. We summarise some of the findings that could change treatments for two of…